Association of Anti–Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma

Cohort study (n=56) suggests anti–PD-1 therapy may be associated with reduced risk of toxic effects, with only 36% (21% with grade 3 or 4 AEs) of patients who experienced severe immune-related adverse effects (AEs) after ipilimumab, experiencing such AEs after anti–PD-1 therapy.


JAMA Dermatology